Form 4: Voyager Therapeutics Director Michael J. Higgins Acquires 24,000 Stock Options

Director Michael J. Higgins acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024.

Summary

• Michael J. Higgins, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options on June 5, 2024.
• The options have an exercise price of $8.70.
• The options were granted under the company's 2015 Stock Option and Incentive Plan, as part of the director compensation policy.
• The options vest upon the earlier of the one-year anniversary of the grant date (June 5, 2024) or the date of the next annual meeting of stockholders, contingent on continued service as a director.
• The options expire on June 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard practice for compensating directors in publicly traded companies, aligning their interests with shareholders through equity ownership.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in the biotechnology industry.
• The vesting schedule of one year or until the next annual meeting is typical for director stock options.
• The exercise price is set at the market price on the grant date, which is standard practice.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates